Volume 10, Issue 3 (Fall 2006)
Physiol Pharmacol 2006, 10(3): 173-181 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghanbari A, Eliassi A. The effect of bromocriptine on basal and histamine-stimulated gastric acid secretion in anesthetized rats . Physiol Pharmacol 2006; 10 (3) :173-181
URL: http://ppj.phypha.ir/article-1-271-en.html
URL: http://ppj.phypha.ir/article-1-271-en.html
Abstract: (13013 Views)
Introduction: The protective and antisecretory effects of dopamine agonists on the
stomach have been already reported, but the effect of bromocriptine (D2 dopamine agonist)
on histamine stimulated gastric acid secretion (GAS) needs to be investigated.
Methods: For gastric sampling, animals were anesthetized and a polyethylen tube was
introduced into the stomach through esophagus. A cannula was also inserted into the
pyloroduodenal junction and passed up into the stomach.
Results: Our data showed that administration of bromocriptine (2 mg/kg), 60 minutes
before histamine infusion, did not affect basal acid secretion but significantly reduced
histamine-induced GAS (P<0.01). Also, simultaneous application of bromocriptine and
histamine-infusion (0.8 mg/100g/h) had no effect on histamine-stimulated gastric acid
secretion. The inhibitory effect of bromocriptine on GAS did not change by sulpiride, a D2
dopamine antagonist. Plasma glucose level was constant in our experimental conditions.
Conclusion: Based on our data, we concluded that inhibitory effect of bromocriptine (2
mg/kg) on histamine stimulated acid output was probably mediated by non dopaminergic
receptors or unknown subtypes of D2 receptors which are not sensitive to sulpiride.
Type of Manuscript: Experimental research article |
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
